These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30625402)

  • 1. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.
    Pape S; Gevers TJG; Belias M; Mustafajev IF; Vrolijk JM; van Hoek B; Bouma G; van Nieuwkerk CMJ; Hartl J; Schramm C; Lohse AW; Taubert R; Jaeckel E; Manns MP; Papp M; Stickel F; Heneghan MA; Drenth JPH
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2068-2075.e2. PubMed ID: 30625402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials.
    Lamers MM; van Oijen MG; Pronk M; Drenth JP
    J Hepatol; 2010 Jul; 53(1):191-8. PubMed ID: 20400196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for autoimmune hepatitis.
    Manns MP; Strassburg CP
    Dig Dis; 2011; 29(4):411-5. PubMed ID: 21894012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.
    Purnak T; Efe C; Kav T; Wahlin S; Ozaslan E
    Dig Dis Sci; 2017 Oct; 62(10):2900-2907. PubMed ID: 28871464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months.
    Pape S; Gevers TJG; Vrolijk JM; van Hoek B; Bouma G; van Nieuwkerk CMJ; Taubert R; Jaeckel E; Manns MP; Papp M; Sipeki N; Stickel F; Efe C; Ozaslan E; Purnak T; Nevens F; Kessener DJN; Kahraman A; Wedemeyer H; Hartl J; Schramm C; Lohse AW; Drenth JPH; Heneghan MA
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1609-1617.e4. PubMed ID: 31715274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents.
    Woynarowski M; Nemeth A; Baruch Y; Koletzko S; Melter M; Rodeck B; Strassburg CP; Pröls M; Woźniak M; Manns MP;
    J Pediatr; 2013 Nov; 163(5):1347-53.e1. PubMed ID: 23810723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine induced biochemical remission in childhood autoimmune hepatitis.
    Franulović OZ; Rajacić N; Lesar T; Kuna AT; Morić BV
    Coll Antropol; 2012 Sep; 36(3):973-9. PubMed ID: 23213960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine Monotherapy Is Equivalent to Dual Therapy in Maintaining Remission in Autoimmune Hepatitis.
    McNally BB; Carey EJ
    Dig Dis Sci; 2021 May; 66(5):1715-1719. PubMed ID: 32436124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis?
    Efe C; Ozaslan E; Purnak T
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1896-1897. PubMed ID: 30807845
    [No Abstract]   [Full Text] [Related]  

  • 11. Budesonide in previously untreated autoimmune hepatitis.
    Wiegand J; Schüler A; Kanzler S; Lohse A; Beuers U; Kreisel W; Spengler U; Koletzko S; Jansen PL; Hochhaus G; Möllmann HW; Pröls M; Manns MP
    Liver Int; 2005 Oct; 25(5):927-34. PubMed ID: 16162148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
    Díaz-González Á; Hernández-Guerra M; Pérez-Medrano I; Sapena V; Riveiro-Barciela M; Barreira-Díaz A; Gómez E; Morillas RM; Del Barrio M; Escudé L; Mateos B; Horta D; Gómez J; Conde I; Ferre-Aracil C; El Hajra I; Arencibía A; Zamora J; Fernández A; Salcedo M; Molina E; Soria A; Estévez P; López C; Álvarez-Navascúes C; García-Retortillo M; Crespo J; Londoño MC;
    Hepatology; 2023 Apr; 77(4):1095-1105. PubMed ID: 36626622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge issues in autoimmune hepatitis.
    Liberal R; Krawitt EL; Vierling JM; Manns MP; Mieli-Vergani G; Vergani D
    J Autoimmun; 2016 Dec; 75():6-19. PubMed ID: 27502148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events related to low dose corticosteroids in autoimmune hepatitis.
    van den Brand FF; van der Veen KS; Lissenberg-Witte BI; de Boer YS; van Hoek B; Drenth JPH; Verdonk RC; Vrolijk JM; van Nieuwkerk CMJ; Bouma G;
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1120-1126. PubMed ID: 31617229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis.
    Dhaliwal HK; Hoeroldt BS; Dube AK; McFarlane E; Underwood JC; Karajeh MA; Gleeson D
    Am J Gastroenterol; 2015 Jul; 110(7):993-9. PubMed ID: 26010310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia.
    Fallatah HI; Akbar HO; Qari YA
    Saudi J Gastroenterol; 2010; 16(2):95-9. PubMed ID: 20339178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda.
    Sebode M; Hartl J; Vergani D; Lohse AW;
    Liver Int; 2018 Jan; 38(1):15-22. PubMed ID: 28432836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune hepatitis treatment in the elderly: A systematic review.
    Durazzo M; Lupi G; Scandella M; Ferro A; Gruden G
    World J Gastroenterol; 2019 Jun; 25(22):2809-2818. PubMed ID: 31236003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.